Jefferies Financial Group upgraded shares of Udg Healthcare (LON:UDG) to a buy rating in a report issued on Thursday. They currently have GBX 890 ($11.52) target price on the stock, down from their previous target price of GBX 895 ($11.59).
Several other equities analysts have also issued reports on the company. Numis Securities reaffirmed a reduce rating on shares of Udg Healthcare in a research report on Wednesday, August 8th. Peel Hunt reaffirmed a buy rating on shares of Udg Healthcare in a research report on Wednesday, August 8th. Liberum Capital reaffirmed a buy rating and issued a GBX 884 ($11.44) price target on shares of Udg Healthcare in a research report on Wednesday, August 8th. Finally, Berenberg Bank lifted their price target on Udg Healthcare from GBX 815 ($10.55) to GBX 850 ($11.00) and gave the stock a hold rating in a research report on Wednesday, June 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Hold and an average price target of GBX 850.67 ($11.01).
Udg Healthcare opened at GBX 746 ($9.66) on Thursday, according to MarketBeat. Udg Healthcare has a 1 year low of GBX 690 ($8.93) and a 1 year high of GBX 963 ($12.47).
Udg Healthcare Company Profile
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services to the healthcare industry in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates through three segments: Ashfield, Sharp, and Aquilant.
Recommended Story: Average Daily Trade Volume Explained
Receive News & Ratings for Udg Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Udg Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.